CAS 129453-61-8 Anti Estrogen Steroids Powder Faslodex / Fulvestrant Acetate

Faslodex / Fulvestrant Acetate CAS 129453-61-8 Anti Estrogen Anaboli Steroid Powder

Description:

Fulvestrant Acetate (Faslodex, AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.

Fulvestrant Acetate is a selective estrogen receptor down-regulator (SERD). Fulvestrant Acetate is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrant Acetate remains under investigation in an attempt to optimize its effectiveness.

Fulvestrant Acetate provided effective second-line therapy in this setting for postmenopausal women who had relapsed or progressed after previous endocrine therapy.

Applications:

Many breast cancers are stimulated to grow by the female sex hormones oestrogen and progesterone. These breast cancers are called hormone sensitive or hormone receptor positive. Drugs that block the effects of these hormones can slow or stop the growth of the breast cancer cells. Fulvestrante stops oestrogen getting to the cancer cells by blocking oestrogen receptors and reducing the number of receptors the cancer cell has.

Fulvestrante (Faslodex, AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.

Fulvestrante is a selective estrogen receptor down-regulator (SERD). Fulvestrante is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrante remains under investigation in an attempt to optimize its effectiveness.

Fulvestrante provided effective second-line therapy in this setting for postmenopausal women who had relapsed or progressed after previous endocrine therapy.

In particular 4 clinical trials in this setting did show similar efficacy to the other hormonal agents (aromatase inhibitors ) with good tolerability profile. Fulvestrante had a lower incidence of joint disorders.

Reason for Choosing us:

1): Superior Quality and Competitive Price:
Our company is a renowned pharmaceutical manufacturer with more than 15 years experiences in China and all powders are supplying from our factory directly.

2): Fast ,Safe and Well Disguised Delievery:
Well-trained and disciplined packing team and sufficient stock ensure the parcel can be delieveried to your hand fastly and safely by DHL, TNT, FedEx, HKEMS, UPS, etc.

3): Experienced in Exporting:
We have clients throughout the world. Products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries. Custome pass rate ≥99%

4): Flexible Payment terms:
T/T,Western Union,Money Gram,Bitcoin. There will always be a term that is convient to you.

5): Warmhearted Customer Service and After-sale Service:
The parcel's photos and tracking numbers will be sent to you once it is prepared. Any of your questions would be solved as soon as possible.

More products: